What is the 13F Pro Quality Score for NSPR?

13F Pro ranks InspireMD, Inc. (NSPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NSPR's current score at https://13fpro.ai/research/NSPR (free sign-up required for the full ranking).

Which hedge funds own the most NSPR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NSPR include Rosalind Advisors,, Nantahala Capital Management,, abrdn plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NSPR as soon as new 13F filings post.

Where does 13F Pro source NSPR data?

All InspireMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. InspireMD, Inc. files with the SEC under CIK 1433607. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NSPR in?

InspireMD, Inc. (NSPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NSPR research updated on 13F Pro?

NSPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

InspireMD, Inc.(NSPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1433607 NSPR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $9.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NSPR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for InspireMD, Inc. (NSPR), a Healthcare sector company. NSPR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $9.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), InspireMD, Inc. reports quarterly revenue of $3.4M, net income of $-13.7M, free cash flow of $-12.5M. Top institutional holders of NSPR by reported 13-F value include Rosalind Advisors,, Nantahala Capital Management,, abrdn plc, based on the most recent SEC filings. NSPR trades on the Nasdaq exchange and files with the SEC under CIK 1433607. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NSPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InspireMD, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$3.4M

Net Income

Q1 2026

$-13.7M

Free Cash Flow

Q1 2026

$-12.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+28.1% YoY

$9.0MFY 2025

FY21 $4.5MFY22 $5.2MFY24 $7.0MFY25 $9.0M

Net Income

-52.4% YoY

$-48.8MFY 2025

FY21 $-14.9MFY22 $-18.5MFY24 $-32.0MFY25 $-48.8M

Operating Income

-48.1% YoY

$-49.6MFY 2025

FY21 $-14.7MFY22 $-18.7MFY24 $-33.5MFY25 $-49.6M

EPS (Diluted)

+0.0% YoY

$-0.76FY 2025

FY21 —FY22 $-2.35FY24 $-0.76FY25 $-0.76

Total Assets

+48.3% YoY

$69.4MFY 2025

FY21 $39.7MFY22 $24.7MFY24 $46.8MFY25 $69.4M

Op. Cash Flow

-60.5% YoY

$-35.1MFY 2025

FY21 $-13.2MFY22 $-15.5MFY24 $-21.9MFY25 $-35.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$9.0M +28.1%	$7.0M +35.5%	$5.2M +15.0%	$4.5M +80.9%	$2.5M -33.2%	$3.7M
Net Income	$-48.8M -52.4%	$-32.0M -73.1%	$-18.5M -24.0%	$-14.9M -41.5%	$-10.5M -5.0%	$-10.0M
Operating Income	$-49.6M -48.1%	$-33.5M -79.0%	$-18.7M -27.2%	$-14.7M -41.8%	$-10.4M -5.7%	$-9.8M
EPS (Diluted)	$-0.76 +0.0%	$-0.76 +67.7%	$-2.35	—	—	—
Total Assets	$69.4M +48.3%	$46.8M +89.9%	$24.7M -37.9%	$39.7M +123.4%	$17.8M +79.9%	$9.9M
Operating Cash Flow	$-35.1M -60.5%	$-21.9M -40.7%	$-15.5M -17.7%	$-13.2M -45.5%	$-9.1M +7.4%	$-9.8M

AI Insight: NSPR Financial Trends

InspireMD burns through equity at an accelerating pace — operating cash outflows hit $12M in Q1 2026 with revenue still anchored at $3M.

• Revenue inched from $2M (Q2 2024–Q2 2025) to $3M (Q3 2025–Q1 2026) — modest but the only bright spot.

• Operating losses widened from -$8M in Q2 2024 to -$14M in Q1 2026, a 75% deterioration over seven quarters.

• Operating cash outflows escalated from -$4M in Q2 2024 to -$12M in Q1 2026, intensifying cash consumption pressure.

• Equity surged from $20M in Q2 2025 to $64M in Q3 2025, indicating a likely capital raise, before declining to $44M in Q1 2026.

⚠ Equity eroded from $64M to $44M in just two quarters — at current burn, runway could be fewer than 4 quarters.

⚠ Net losses hit -$14M in Q1 2026 against only $3M revenue; the path to operational self-sufficiency remains undefined.

⚠ No debt reported across all periods — watch for any debt issuance as equity cushion thins, which would add leverage risk.

AI Insight: NSPR Ratio Trends

InspireMD's returns remain deeply negative across all periods, with ROA worsening to -97.0% in Q1 2026 from -64.8% in Q3 2025.

• ROA deteriorated sharply from -64.8% in Q3 2025 to -97.0% in Q1 2026, signaling accelerating capital consumption.

• ROE swung to -125.5% in Q1 2026 after a partial recovery to -79.3% and -85.2% in Q3–Q4 2025.

• ROIC was -81.4% in Q3 2025 and -87.6% in Q4 2025; no improvement visible across available data points.

⚠ OpMargin and NPM are entirely absent across all periods — inability to track profitability progress is a significant analytical gap.

⚠ TTM ROA of -90.9% and ROE of -117.6% suggest the quarterly deterioration in Q1 2026 is not an isolated event.

Get alerted when NSPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for InspireMD, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NSPR

Rosalind Advisors, Inc.
$6.4M3,905,743 sh
Nantahala Capital Management, LLC
$5.5M3,376,484 sh
abrdn plc
$5.2M3,173,364 sh
ORBIMED ADVISORS LLC
$5.1M3,133,405 sh
Parkman Healthcare Partners LLC
$3.9M2,416,518 sh
Velan Capital Investment Management LP
$3.4M2,099,652 sh
MARSHALL WACE, LLP
$3.0M1,860,405 sh
Soleus Capital Management, L.P.
$1.7M1,045,708 sh
PURA VIDA INVESTMENTS, LLC
$734.3K450,517 sh
Affiance Financial, LLC
$408.1K250,370 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$6.4M	3,905,743
Nantahala Capital Management, LLC	$5.5M	3,376,484
abrdn plc	$5.2M	3,173,364
ORBIMED ADVISORS LLC	$5.1M	3,133,405
Parkman Healthcare Partners LLC	$3.9M	2,416,518
Velan Capital Investment Management LP	$3.4M	2,099,652
MARSHALL WACE, LLP	$3.0M	1,860,405
Soleus Capital Management, L.P.	$1.7M	1,045,708
PURA VIDA INVESTMENTS, LLC	$734.3K	450,517
Affiance Financial, LLC	$408.1K	250,370

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NSPR on your watchlist

Track score changes the day InspireMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NSPR a good stock to buy?

13F Pro's AI-powered analysis of InspireMD, Inc. (NSPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NSPR are available on the NSPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NSPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NSPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of InspireMD, Inc.'s investment landscape.